{"id":"anti-r-il2-cyclosporine-then-everolimus","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (bacterial, viral, fungal)"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hyperlipidemia"},{"rate":null,"effect":"Bone marrow suppression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Anti-R-IL2 (anti-IL-2 receptor) monoclonal antibodies block IL-2 signaling on T cells, reducing their proliferation. Cyclosporine inhibits calcineurin-dependent T-cell activation. Everolimus, an mTOR inhibitor, further suppresses T-cell and B-cell proliferation. This sequential approach targets multiple checkpoints in the immune response to prevent organ transplant rejection.","oneSentence":"This combination therapy sequentially suppresses T-cell activation via anti-IL-2 receptor blockade and calcineurin inhibition, followed by mTOR inhibition to prevent allograft rejection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:55.204Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allograft rejection prevention in organ transplantation"}]},"trialDetails":[{"nctId":"NCT06504225","phase":"","title":"EVEROLD LONG TERM FOLLOW-UP","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2024-08-23","conditions":"Transplant; Complication, Failure","enrollment":260},{"nctId":"NCT01028092","phase":"PHASE3","title":"mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2009-03","conditions":"Renal Transplant","enrollment":327}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Anti R-IL2 + Cyclosporine then Everolimus","genericName":"Anti R-IL2 + Cyclosporine then Everolimus","companyName":"University Hospital, Brest","companyId":"university-hospital-brest","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination therapy sequentially suppresses T-cell activation via anti-IL-2 receptor blockade and calcineurin inhibition, followed by mTOR inhibition to prevent allograft rejection. Used for Allograft rejection prevention in organ transplantation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}